Published On: Mon, Sep 12th, 2016

Recent Analysts’ Ratings Changes for Relypsa (RLYP)

A number of firms have modified their ratings and price targets on shares of Relypsa (NASDAQ: RLYP) recently:

9/1/2016 – Relypsa was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating. They now have a $32.00 price target on the stock.
9/1/2016 – Relypsa was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.
8/24/2016 – Relypsa was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $34.01 price target on the stock.
8/22/2016 – Relypsa was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $32.00 price target on the stock.
8/13/2016 – Relypsa had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $32.00 price target on the stock.
8/8/2016 – Relypsa had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $32.00 price target on the stock.
7/26/2016 – Relypsa was downgraded by analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating. They now have a $32.00 price target on the stock, down previously from $41.00.
7/24/2016 – Relypsa had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $32.00 price target on the stock, up previously from $20.00.
7/22/2016 – Relypsa was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $32.00 price target on the stock.
7/21/2016 – Relypsa had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.
7/21/2016 – Relypsa was downgraded by analysts at Brean Capital from a “buy” rating to a “hold” rating.
7/21/2016 – Relypsa was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $32.00 price target on the stock, up previously from $25.00.
7/21/2016 – Relypsa was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating. They now have a $32.00 price target on the stock, up previously from $9.00.
7/21/2016 – Relypsa was given a new $41.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
7/18/2016 – Relypsa had its “buy” rating reaffirmed by analysts at Brean Capital. They now have a $26.00 price target on the stock.
7/15/2016 – Relypsa had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $35.00 price target on the stock.
7/15/2016 – Relypsa had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $36.00 price target on the stock.

Shares of Relypsa Inc. (NASDAQ:RLYP) opened at 31.99 on Monday. The stock’s 50 day moving average price is $30.31 and its 200-day moving average price is $20.28. Relypsa Inc. has a 12 month low of $10.26 and a 12 month high of $32.12.
Relypsa (NASDAQ:RLYP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by $0.31. The business had revenue of $5.22 million for the quarter, compared to analysts’ expectations of $5.45 million. On average, equities research analysts expect that Relypsa Inc. will post ($6.41) earnings per share for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/recent-analysts-ratings-changes-for-relypsa-rlyp.html

In other news, major shareholder Orbimed Advisors Llc sold 4,043,600 shares of Relypsa stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $32.00, for a total value of $129,395,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder James D. Dondero sold 37,000 shares of Relypsa stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $31.96, for a total transaction of $1,182,520.00. The disclosure for this sale can be found here.
Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Receive News & Ratings for Relypsa Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Relypsa Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>